Neonatal hyperbilirubinaemia following the use of prostaglandin E2 in labour.
A prospective study of 447 labours and the resulting newborn failed to reveal any significant difference between the incidence of neonatal hyperbilirubinaemia, defined as a level of at least 205 mumol/l (12 mg/100 ml), following spontaneous labour and after labour induced or accelerated with prostaglandin E2 (PGE2). The incidence of unexplained neonatal hyperbilirubinaemia after spontaneous labour was 4-5 per cent. There was no significant association between the incidence of neonatal hyperbilirubinaemia and the total dose of PGE2 used for induction. None of the babies of the six mothers who required more than 1-5 mg of PGE2 to induce labour developed hyperbilirubinaemia. No association was demonstrated between neonatal hyperbilirubinaemia and birth weight or the duration of labour. The implications of these findings are discussed.
D001724:Birth Weight; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000453:epidemiology; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000209:etiology*; D007751:Labor, Induced; D010121:Oxytocin / Q000627:therapeutic use; D011247:Pregnancy; D011458:Prostaglandins E / Q000009:adverse effects / Q000627:therapeutic use*
D011458:Prostaglandins E; D010121:Oxytocin